Article
Quantification of plasma mutant calreticulin for diagnosis and therapeutic response assessment of peginterferon-α in myeloproliferative neoplasms: A proof-of-concept study.
Clinica chimica acta; international journal of clinical chemistry - 15 Feb 2026
Tian Jingjing, Tang Xuemei, Zhou Weiyan, Yang Can, Zhang Qingyun, Wu Quanli, Ma Xiaotong, Tang Gusheng, Guan Ming, Wu Zhiyuan
Abstract excerpt
BACKGROUND: Calreticulin (CALR) exon 9 mutations are drivers in essential thrombocythemia (ET) and primary myelofibrosis (PMF). These mutations lead to extracellular secretion of mutant CALR, but a quantitative plasma assay to leverage this for management is lacking. OBJECTIVE: To develop and validate a quantitative method based on homemade monoclonal antibody (McAb) targeting mutant CALR for diagnosing ET and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.